CYCCP - Cyclacel Pharmaceuticals, Inc.
| Previous Close | 5.73 |
| Open | 6.10 |
| Bid | 0.50 x 1800 |
| Ask | 6.35 x 900 |
| Day's Range | 6.10 - 6.10 |
| 52 Week Range | 3.87 - 6.39 |
| Volume | 277 |
| Avg. Volume | 262 |
| Market Cap | 11.599M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.49 |
| Earnings Date | Feb 25, 2020 |
| Forward Dividend & Yield | 0.60 (9.76%) |
| Ex-Dividend Date | Apr 13, 2020 |
| 1y Target Est | N/A |
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib-venetoclax Combination in Patients with Relapsed or.
- Zacks
Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?
We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results
BERKELEY HEIGHTS, N.J., Feb. 19, 2020 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the BIO CEO & Investor Conference at 11:15 a.m. EST on Monday, February 10, in the Wilder Room at the New York Marriott Marquis. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in its key programs. A live webcast of the presentation will be available through the Company's website: www.cyclacel.com.
- GlobeNewswire
Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2019 achievements and outlining the Company’s key business objectives for 2020. Cyclacel’s clinical and business strategy will be highlighted at a presentation during Biotech Showcase™ 2020 on Monday, January 13, 2019 at 9:30 a.m. PT in the Yosemite A Suite (Ballroom level) at the Hilton San Francisco Union Square. "During 2019 we have been excited to observe evidence of anticancer activity with CYC065, our CDK2/9 inhibitor, in patients with both solid and liquid cancers,” said Spiro Rombotis, President and Chief Executive Officer.
- GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech Showcase™ 2020, at 9:30 a.m. PT on January 13, in the Yosemite A (Ballroom level) at the Hilton San Francisco Union Square. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. A live webcast of the presentation will be available through the Company's website: www.cyclacel.com.
- GlobeNewswire
Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
BERKELEY HEIGHTS, N.J., Dec. 09, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results
– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J.,.
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results
BERKELEY HEIGHTS, N.J., Nov. 07, 2019 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 23, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient with an oral formulation of CYC065, a CDK2/9 inhibitor, in part 3 of a Phase 1 study (CYC065-01) which is evaluating single agent CYC065 in patients with advanced solid cancers. Parts 1 and 2 of the study are evaluating CYC065 administered as an intravenous infusion. “We are excited to report that the first patient has been treated with oral CYC065 in part 3 of our Phase 1 study,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.
- GlobeNewswire
Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
BERKELEY HEIGHTS, N.J., Sept. 04, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results
- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 13, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel".
- Benzinga
The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down ...
- Benzinga
The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 07, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient in a Phase 1/2 study evaluating the safety and effectiveness of oral sapacitabine, a nucleoside analogue, in combination with oral venetoclax, a BCL2 inhibitor, in patients with relapsed or refractory AML or MDS. “Sapacitabine is an oral nucleoside analogue that is active in AML and MDS that is relapsed or refractory to prior therapy such as cytarabine or hypomethylating agents.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For May 24
Tesla Inc (NASDAQ: TSLA ) shares dropped 2.5 percent to $190.52. The stock rebounded above $200 on Thursday on news of a purported internal email from Musk on the company's fourth-quarter deliveries. ...
- GlobeNewswire
Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results
BERKELEY HEIGHTS, N.J., May 14, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019
BERKELEY HEIGHTS, N.J., April 01, 2019 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing.
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
– Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J., March 27, 2019 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel".
- Benzinga
The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 26) Baxter International Inc (NYSE: BAX ) Biohaven Pharmaceutical ...
- Benzinga
Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action
Penny stock Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) was sinking lower Tuesday after the nanocap biotech 's announcement concerning a paper published by independent investigators in the Journal of ...
